An expert reviews important considerations for chronic kidney disease (CKD) screening, cardiovascular risk, and how to integrate the recently approved therapy, finerenone, into the management of patients with type 2 diabetes and CKD.
NPs and PAs in primary care
This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
George L. Bakris, MD: consultant/advisor/speaker: Alnylam, AstraZeneca, Bayer, DiaMedica Therapeutics, Horizon, Ionis, KBP Biosciences, Merck, Novo Nordisk, Quantum Genomics.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. PRP4654-CT